Explosive growth of antidiabetic SGLT-2 inhibitors, exceeding KRW 10 billion sales
Antidiabetic SGLT-2 inhibitors have continued explosive growths.
Currently, drugs which have been launched in the market with the health insurance benefit are AstraZeneca’s ‘Forxiga’ and Astellas’s Suglat.
When it comes to the two drugs, Forxiga is about to become a blockbuster as exceeding KRW...
Fees
- Email service daily and homepage access.
- $300 per month. ($3,240 per year)
- 5 Email holders per each company.
- Anual contract base.
